A Phase 2, Open-Label, Multicenter, Randomized Study to Evaluate the Pharmacokinetics and Safety of Twice Yearly Long-Acting Subcutaneous Lenacapavir for Pre-Exposure Prophylaxis in People Who Inject Drugs (PURPOSE 4)
The goals of this clinical study are to look at how lenacapavir (LEN) passes through the body and to assess the safety of LEN and emtricitabine/tenofovir disoproxil fumarate (F/TDF) for pre-exposure prophylaxis (PrEP) in people who inject drugs (PWID) in the United States (US). The primary objectives of this study are to characterize the pharmacokinetics (PK) of LEN and to evaluate the safety of LEN and F/TDF for PrEP in US PWID.
View MoreAge
18 Years +
Sex
All
Healthy Volunteers
Accepts Healthy Volunteers
Medical Condition
Pre-Exposure Prophylaxis of HIV Infection
Gender
N/A
Date
December 2023 - July 2027
Study Type
Interventional
Study Phase
Phase 2
Product
Lenacapavir Injection, Lenacapavir Tablet, Emtricitabine/tenofovir disoproxil fumarate (F/TDF)
San Diego, California, United States, 92103
Share Trial